Regentis Biomaterials Ltd. (AMEX: RGNT) Stock Competitors & Peer Comparison

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ISRG has a market cap of 132.3B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ISRG trades at $374.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ISRG's P/E ratio is 38.93. In terms of profitability, RGNT's ROE is N/A, compared to ISRG's ROE of +0.18%. Regarding short-term risk, RGNT is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ISRG's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while BDXA trades at $59.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas BDXA's P/E ratio is 45.70. In terms of profitability, RGNT's ROE is N/A, compared to BDXA's ROE of +0.04%. Regarding short-term risk, RGNT is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BDXA's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, BDX has a market cap of 51.7B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while BDX trades at $187.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas BDX's P/E ratio is 14.43. In terms of profitability, RGNT's ROE is N/A, compared to BDX's ROE of +0.04%. Regarding short-term risk, RGNT is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BDX's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, MDLN has a market cap of 27.5B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while MDLN trades at $32.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas MDLN's P/E ratio is 23.87. In terms of profitability, RGNT's ROE is N/A, compared to MDLN's ROE of +0.05%. Regarding short-term risk, RGNT is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MDLN's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, WST has a market cap of 24.9B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while WST trades at $353.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas WST's P/E ratio is 44.41. In terms of profitability, RGNT's ROE is N/A, compared to WST's ROE of +0.19%. Regarding short-term risk, RGNT is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check WST's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while HOLX trades at $76.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas HOLX's P/E ratio is 31.54. In terms of profitability, RGNT's ROE is N/A, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RGNT is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HOLX's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, SOLV has a market cap of 15.3B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while SOLV trades at $88.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas SOLV's P/E ratio is 12.48. In terms of profitability, RGNT's ROE is N/A, compared to SOLV's ROE of +0.29%. Regarding short-term risk, RGNT is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check SOLV's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, COO has a market cap of 14.9B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while COO trades at $76.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas COO's P/E ratio is 16.70. In terms of profitability, RGNT's ROE is N/A, compared to COO's ROE of +0.03%. Regarding short-term risk, RGNT is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check COO's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while BDXB trades at $48.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RGNT's ROE is N/A, compared to BDXB's ROE of +0.04%. Regarding short-term risk, RGNT is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BDXB's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, BAX has a market cap of 13.7B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while BAX trades at $26.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas BAX's P/E ratio is 12.69. In terms of profitability, RGNT's ROE is N/A, compared to BAX's ROE of -0.17%. Regarding short-term risk, RGNT is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BAX's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, RGEN has a market cap of 10.2B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while RGEN trades at $180.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas RGEN's P/E ratio is 100.16. In terms of profitability, RGNT's ROE is N/A, compared to RGEN's ROE of +0.02%. Regarding short-term risk, RGNT is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check RGEN's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, AVTR has a market cap of 9.6B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while AVTR trades at $14.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas AVTR's P/E ratio is 16.76. In terms of profitability, RGNT's ROE is N/A, compared to AVTR's ROE of -0.10%. Regarding short-term risk, RGNT is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check AVTR's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ATR has a market cap of 8.5B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ATR trades at $132.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ATR's P/E ratio is 23.24. In terms of profitability, RGNT's ROE is N/A, compared to ATR's ROE of +0.14%. Regarding short-term risk, RGNT is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATR's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while BLCO trades at $17.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas BLCO's P/E ratio is 26.46. In terms of profitability, RGNT's ROE is N/A, compared to BLCO's ROE of -0.03%. Regarding short-term risk, RGNT is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BLCO's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, STVN has a market cap of 6.1B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while STVN trades at $22.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas STVN's P/E ratio is 33.89. In terms of profitability, RGNT's ROE is N/A, compared to STVN's ROE of +0.09%. Regarding short-term risk, RGNT is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check STVN's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, TFX has a market cap of 6B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while TFX trades at $134.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas TFX's P/E ratio is 15.44. In terms of profitability, RGNT's ROE is N/A, compared to TFX's ROE of -0.32%. Regarding short-term risk, RGNT is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check TFX's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, MMSI has a market cap of 5.4B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while MMSI trades at $90.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas MMSI's P/E ratio is 23.09. In terms of profitability, RGNT's ROE is N/A, compared to MMSI's ROE of +0.09%. Regarding short-term risk, RGNT is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MMSI's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ICUI trades at $182.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ICUI's P/E ratio is 22.79. In terms of profitability, RGNT's ROE is N/A, compared to ICUI's ROE of +0.01%. Regarding short-term risk, RGNT is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ICUI's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, NVST has a market cap of 4.4B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while NVST trades at $26.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas NVST's P/E ratio is 18.33. In terms of profitability, RGNT's ROE is N/A, compared to NVST's ROE of +0.04%. Regarding short-term risk, RGNT is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check NVST's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, PLSE has a market cap of 3.3B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while PLSE trades at $47.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas PLSE's P/E ratio is -39.85. In terms of profitability, RGNT's ROE is N/A, compared to PLSE's ROE of -0.94%. Regarding short-term risk, RGNT is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check PLSE's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ATRC has a market cap of 2.4B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ATRC trades at $47.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ATRC's P/E ratio is 1474.84. In terms of profitability, RGNT's ROE is N/A, compared to ATRC's ROE of +0.02%. Regarding short-term risk, RGNT is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATRC's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, XRAY has a market cap of 2.2B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while XRAY trades at $10.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas XRAY's P/E ratio is 7.54. In terms of profitability, RGNT's ROE is N/A, compared to XRAY's ROE of -0.40%. Regarding short-term risk, RGNT is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check XRAY's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while LMAT trades at $82.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas LMAT's P/E ratio is 30.26. In terms of profitability, RGNT's ROE is N/A, compared to LMAT's ROE of +0.16%. Regarding short-term risk, RGNT is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check LMAT's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while BLFS trades at $36.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas BLFS's P/E ratio is -174.92. In terms of profitability, RGNT's ROE is N/A, compared to BLFS's ROE of +0.13%. Regarding short-term risk, RGNT is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BLFS's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, AZTA has a market cap of 1.7B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while AZTA trades at $36.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas AZTA's P/E ratio is 86.93. In terms of profitability, RGNT's ROE is N/A, compared to AZTA's ROE of -0.08%. Regarding short-term risk, RGNT is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check AZTA's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while KMTS trades at $27.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas KMTS's P/E ratio is -11.55. In terms of profitability, RGNT's ROE is N/A, compared to KMTS's ROE of -0.59%. Regarding short-term risk, RGNT is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check KMTS's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while STAA trades at $23.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas STAA's P/E ratio is 40.47. In terms of profitability, RGNT's ROE is N/A, compared to STAA's ROE of +0.01%. Regarding short-term risk, RGNT is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check STAA's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, QDEL has a market cap of 1B. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while QDEL trades at $14.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas QDEL's P/E ratio is 11.08. In terms of profitability, RGNT's ROE is N/A, compared to QDEL's ROE of -0.55%. Regarding short-term risk, RGNT is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check QDEL's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ATRI trades at $459.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RGNT's ROE is N/A, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RGNT is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATRI's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ANGO has a market cap of 653.9M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ANGO trades at $15.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ANGO's P/E ratio is -40.56. In terms of profitability, RGNT's ROE is N/A, compared to ANGO's ROE of -0.21%. Regarding short-term risk, RGNT is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ANGO's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, NNNN has a market cap of 321.7M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while NNNN trades at $7.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas NNNN's P/E ratio is 105.92. In terms of profitability, RGNT's ROE is N/A, compared to NNNN's ROE of +0.27%. Regarding short-term risk, RGNT is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check NNNN's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, SMTI has a market cap of 314.8M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while SMTI trades at $34.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas SMTI's P/E ratio is -570.67. In terms of profitability, RGNT's ROE is N/A, compared to SMTI's ROE of -4.74%. Regarding short-term risk, RGNT is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check SMTI's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, OSUR has a market cap of 257.5M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while OSUR trades at $3.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas OSUR's P/E ratio is -6.80. In terms of profitability, RGNT's ROE is N/A, compared to OSUR's ROE of -0.15%. Regarding short-term risk, RGNT is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check OSUR's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, INFU has a market cap of 246M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while INFU trades at $12.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas INFU's P/E ratio is 29.73. In terms of profitability, RGNT's ROE is N/A, compared to INFU's ROE of +0.15%. Regarding short-term risk, RGNT is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check INFU's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, UTMD has a market cap of 227.4M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while UTMD trades at $71.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas UTMD's P/E ratio is 21.13. In terms of profitability, RGNT's ROE is N/A, compared to UTMD's ROE of +0.09%. Regarding short-term risk, RGNT is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check UTMD's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, PDEX has a market cap of 211.7M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while PDEX trades at $66.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas PDEX's P/E ratio is 23.35. In terms of profitability, RGNT's ROE is N/A, compared to PDEX's ROE of +0.29%. Regarding short-term risk, RGNT is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check PDEX's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, KRMD has a market cap of 150.2M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while KRMD trades at $3.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas KRMD's P/E ratio is -81.75. In terms of profitability, RGNT's ROE is N/A, compared to KRMD's ROE of -0.11%. Regarding short-term risk, RGNT is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check KRMD's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, MBOT has a market cap of 67.9M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while MBOT trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas MBOT's P/E ratio is -5.73. In terms of profitability, RGNT's ROE is N/A, compared to MBOT's ROE of -0.22%. Regarding short-term risk, RGNT is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MBOT's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while AKYA trades at $1.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RGNT's ROE is N/A, compared to AKYA's ROE of -1.80%. Regarding short-term risk, RGNT is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check AKYA's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, DXR has a market cap of 58.4M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while DXR trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas DXR's P/E ratio is 5.51. In terms of profitability, RGNT's ROE is N/A, compared to DXR's ROE of +0.22%. Regarding short-term risk, RGNT is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check DXR's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while STSS trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas STSS's P/E ratio is -0.02. In terms of profitability, RGNT's ROE is N/A, compared to STSS's ROE of -1.54%. Regarding short-term risk, RGNT is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check STSS's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while OMIC trades at $20.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RGNT's ROE is N/A, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RGNT is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check OMIC's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while IGAP trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RGNT's ROE is N/A, compared to IGAP's ROE of +1.80%. Regarding short-term risk, RGNT is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IGAP's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, POCI has a market cap of 48.6M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while POCI trades at $4.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas POCI's P/E ratio is -6.17. In terms of profitability, RGNT's ROE is N/A, compared to POCI's ROE of -0.37%. Regarding short-term risk, RGNT is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check POCI's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, NEPH has a market cap of 48.4M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while NEPH trades at $4.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas NEPH's P/E ratio is 74.33. In terms of profitability, RGNT's ROE is N/A, compared to NEPH's ROE of +0.16%. Regarding short-term risk, RGNT is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NEPH's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, MLSS has a market cap of 41.7M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while MLSS trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas MLSS's P/E ratio is -7.85. In terms of profitability, RGNT's ROE is N/A, compared to MLSS's ROE of -1.49%. Regarding short-term risk, RGNT is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check MLSS's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, HBIO has a market cap of 34.1M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while HBIO trades at $7.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas HBIO's P/E ratio is -20.97. In terms of profitability, RGNT's ROE is N/A, compared to HBIO's ROE of -0.92%. Regarding short-term risk, RGNT is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check HBIO's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while SDC trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas SDC's P/E ratio is -0.03. In terms of profitability, RGNT's ROE is N/A, compared to SDC's ROE of -1.96%. Regarding short-term risk, RGNT is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check SDC's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while IVC trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas IVC's P/E ratio is -0.79. In terms of profitability, RGNT's ROE is N/A, compared to IVC's ROE of -0.46%. Regarding short-term risk, RGNT is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IVC's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ZJYL has a market cap of 24.3M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ZJYL trades at $3.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ZJYL's P/E ratio is 19.44. In terms of profitability, RGNT's ROE is N/A, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RGNT is more volatile compared to ZJYL. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ZJYL's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, RVP has a market cap of 21.8M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while RVP trades at $0.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas RVP's P/E ratio is -2.21. In terms of profitability, RGNT's ROE is N/A, compared to RVP's ROE of -0.05%. Regarding short-term risk, RGNT is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check RVP's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, FEMY has a market cap of 8.2M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while FEMY trades at $2.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas FEMY's P/E ratio is -7.54. In terms of profitability, RGNT's ROE is N/A, compared to FEMY's ROE of -2.26%. Regarding short-term risk, RGNT is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check FEMY's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while NSTG trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RGNT's ROE is N/A, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RGNT is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NSTG's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, LUCY has a market cap of 4.3M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while LUCY trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas LUCY's P/E ratio is -0.41. In terms of profitability, RGNT's ROE is N/A, compared to LUCY's ROE of -0.89%. Regarding short-term risk, RGNT is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check LUCY's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while POAI trades at $4.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas POAI's P/E ratio is -0.03. In terms of profitability, RGNT's ROE is N/A, compared to POAI's ROE of -21.19%. Regarding short-term risk, RGNT is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check POAI's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, NXGL has a market cap of 3.3M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while NXGL trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas NXGL's P/E ratio is -0.55. In terms of profitability, RGNT's ROE is N/A, compared to NXGL's ROE of -1.33%. Regarding short-term risk, RGNT is more volatile compared to NXGL. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check NXGL's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, GCTK has a market cap of 2.6M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while GCTK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas GCTK's P/E ratio is -0.02. In terms of profitability, RGNT's ROE is N/A, compared to GCTK's ROE of -21.36%. Regarding short-term risk, RGNT is more volatile compared to GCTK. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check GCTK's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while MHUA trades at $7.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas MHUA's P/E ratio is 0.25. In terms of profitability, RGNT's ROE is N/A, compared to MHUA's ROE of +0.07%. Regarding short-term risk, RGNT is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MHUA's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while GMVD trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RGNT's ROE is N/A, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RGNT is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check GMVD's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while GMVDW trades at $7.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RGNT's ROE is N/A, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, RGNT is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check GMVDW's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while NXGLW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, RGNT's ROE is N/A, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, RGNT is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check NXGLW's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while AVGR trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RGNT's ROE is N/A, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RGNT is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check AVGR's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while LUCYW trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas LUCYW's P/E ratio is N/A. In terms of profitability, RGNT's ROE is N/A, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, RGNT is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check LUCYW's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, APR has a market cap of 0. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while APR trades at $37.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas APR's P/E ratio is 22.59. In terms of profitability, RGNT's ROE is N/A, compared to APR's ROE of +9.81%. Regarding short-term risk, RGNT is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check APR's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, HRC has a market cap of 0. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while HRC trades at $155.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas HRC's P/E ratio is 41.92. In terms of profitability, RGNT's ROE is N/A, compared to HRC's ROE of +0.14%. Regarding short-term risk, RGNT is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HRC's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, IIN has a market cap of 0. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while IIN trades at $24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas IIN's P/E ratio is 226.45. In terms of profitability, RGNT's ROE is N/A, compared to IIN's ROE of -0.00%. Regarding short-term risk, RGNT is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IIN's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ALOG trades at $83.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ALOG's P/E ratio is 40.93. In terms of profitability, RGNT's ROE is N/A, compared to ALOG's ROE of -0.15%. Regarding short-term risk, RGNT is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ALOG's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while IVTY trades at $7.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas IVTY's P/E ratio is -3.80. In terms of profitability, RGNT's ROE is N/A, compared to IVTY's ROE of -2.40%. Regarding short-term risk, RGNT is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IVTY's competition here

Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGNT stands at 14.5M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RGNT is priced at $2.06 on the AMEX, while ATRS trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGNT currently has a P/E ratio of -0.09, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RGNT's ROE is N/A, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RGNT is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATRS's competition here